Tags : Rilpivirine


ViewPoints Interview: ViiV Healthcare’s Kimberly Smith Shares Insight on Data

In a recent interview with PharmaShots, Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare shared information on the positive findings presented at the 2020 Infectious Diseases Society of America (IDWeek) and the impact of COVID-19 on the development of long-acting cabotegravir and rilpivirine. Shots: The company reported the positive findings of […]Read More

Clinical Trials

ViiV Healthcare Present Results of Long-Acting Cabotegravir and Rilpivirine at

Shots: The company reported the positive findings of a pooled analysis of six ongoing clinical studies which includes P-IIb/IIIb LATTE-2, ATLAS, ATLAS-2M, FLAIR, POLAR, and CUSTOMIZE studies evaluating long-acting cabotegravir and rilpivirine regimen in 1,744 patients with HIV-1 infection across 16 countries The positive findings showed 93% of participants maintained their injection visits amid the […]Read More


ViiV Healthcare Reports Submission of MAA to EMA for the

Shots: The MAA is based on P-III ATLAS and FLAIR studies results assessing cabotegravir + rilpivirine (monthly injectable) in 1,100+ patients with HIV-1 infection with suppressed viral load who are not resistant to cabotegravir or rilpivirine demonstrated similar efficacy to 3-drug oral regimen The EMA’s MAA follows NDA submission of dual regimen to the US […]Read More